hematopoietic system
• mice exhibit a mild reduction in red blood cell count and increase in mean red blood cell volume after poly (IC) treatment, indicating macrocytic anemia
|
• binucleated erythroid cells and hypo-segmented neutrophils are seen in the bone marrow cells occasionally in poly (IC) treated mice
• megakaryocytes occasionally form clusters in poly (IC) treated mice
• these dysplastic features affect less than 1% of bone marrow cells and are not seen in the peripheral blood
|
• mice show a mild reduction in red blood cell count after poly (IC) treatment
• however, platelet numbers are normal, bone marrow cellularity and spleen size are normal after poly (IC) treatment
|
• mice show a mild reduction in hematocrit after poly (IC) treatment
|
• mice show a mild reduction in hemoglobin concentration after poly (IC) treatment
|
• mice show a mild increase in mean corpuscular volume after poly (IC) treatment
|
• poly (IC) treated mice show a nearly 50% reduction in numbers of white blood cells, with decreases in all major lineages and the most marked reduction in B220+ B cells
|
• the hematopoietic stem cell- and progenitor-enriched LSK cells (Lin-Sca-1+C-Kit+) are decreased in the bone marrow at 36 weeks after poly (IC) treatment; decrease in the LSK cells is due to the reduction of short-term and long-term HSCs (CD48-CD150- and CD48-CD150+, respectively) but not the multipotent progenitors in the bone marrow
• however, no differences are seen in the percentages of Lin- cells and MPs after poly (IC) treatment
|
immune system
• poly (IC) treated mice show a nearly 50% reduction in numbers of white blood cells, with decreases in all major lineages and the most marked reduction in B220+ B cells
|
mortality/aging
N |
• poly (IC) treated mice exhibit a normal life span
|
neoplasm